 |
|
|
||||||||||||||
 |
|
|
Tethys Bioscience is dedicated to the discovery, development and commercialization of novel biological markers — biomarkers — that provide a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes.
By developing new tests that use protein and other bloodborne biomarkers to identify people at high risk for devastating and preventable diseases, we can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers give a snapshot of an individual's current risk, which may be modifiable. Our goal is to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Our research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk.
We approach the market with a unique combination of strengths:
- A research, management and commercialization team with extensive experience in diagnostic innovation
- Alliances with world-class researchers and partners
- A solid financial foundation
The company has become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: Biomarkers. The company believes there is a large unmet need in both the discovery of potentially important biomarkers and the eventual use of them in routine clinical practice for many significant diseases.
Tethys Bioscience has built expertise, created significant intellectual property, and is executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. Tethys is focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients.
- Biomarker discovery efforts are focused on applying advanced research tools to identify important biomarkers associated with diseases that affect many people and are very costly to health care systems throughout the world today.
- Clinical validation involves a complex process that results in defining a set of new biomarkers and the application of the resulting test to enhance current clinical practice.
- Value creation encompasses the use of sophisticated health economic analyses to define appropriate performance criteria for new biomarkers and the execution of market development strategies to drive the adoption of new biomarkers in clinical practice.
Nov 9, 2009
Tethys Bioscience Raises $25 Million in Series D Financing
The financing round is led by aeris Capital with George Rehm taking a seat on the Tethys board.
Oct 20, 2009
Gazing into the Future
(Journal of Life Sciences, Fall 2009)
Sep 24, 2009
A preemptive strike on diabetes: Emeryville's Tethys Biosciences rolls out pre-diabetes test
Tethys Bioscience featured in the September/October 2009 issue of Healthcare Journal of Northern California.
Aug 31, 2009
Personnel Additions and Promotions at Tethys Bioscience
Management Team in Position for Full Commercialization of its Line of Personalized-Prevention Diagnostics
Jul 15, 2009
Peer-Reviewed Publications Demonstrate Tethys Bioscience's Ability to Identify those at Highest Risk of Developing Type 2 Diabetes within Five Years
Diabetes journals publish two definitive papers supporting both the science behind and the clinical performance of lead product, the PreDx™ Diabetes Risk Score (DRS)
Jun 7, 2009
New Data in Support of Tethys Bioscience's PreDx™ Diabetes Risk Score Presented at ADA Scientific Sessions
New data support cost-effectiveness and clinical utility of a risk assessment test for type 2 diabetes